Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Substance misuse and alcohol use disorders. In: Evidence-based geriatric nursing protocols for best practice.

BIBLIOGRAPHIC SOURCE(S)

  • Naegle M. Substance misuse and alcohol use disorders. In: Capezuti E, Zwicker D, Mezey M, Fulmer T, editor(s). Evidence-based geriatric nursing protocols for best practice. 3rd ed. New York (NY): Springer Publishing Company; 2008. p. 649-76. [71 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Levels of evidence (I – VI) are defined at the end of the "Major Recommendations" field.

Parameters of Assessment

Nursing Care Strategies

  • At-risk Drinking (consumption of alcohol in excess of one drink per day for seven days a week or more than three drinks on any one occasion):
    • Hydrate with clear fluid by mouth (p.o.) as indicated. Limit use of intravenous fluid except as necessary. Hospitalize if:
      • Blood alcohol level (BAL) >100 mg/dL
      • Severe withdrawal symptoms
      • Suicidal ideation or attempts
      • Comorbid conditions that compromise treatment
      • Polysubstance dependence
    • Conduct Brief Intervention (FRAMES) (Dyehouse, Howe, & Ball, 1996 [Level VI]).
      • Feedback information to patients about current health problems or potential problems associated with their level of consumption.
      • Responsible choice about how to respond to the information provided to the patients is their choice.
      • Advice must be clear about drinking their amounts and recommended moderate levels of drinking.
      • Menu of choices is provided by the nurse to the patient/client regarding future drinking behaviors.
      • Empathy is essential to the exchange. Offer information based on scientific evidence, acknowledge the difficulty of change, avoid confrontation.
      • Self-efficacy of the individual is supported and the nurse helps patient explore options for change.
  • Smoking cigarettes or using smokeless tobacco.
    • Apply the Five A's Intervention ("Treating tobacco," 2008)
      • Ask: Identify and document tobacco use.
      • Advise: Urge the user to quit in a strong personalized manner.
      • Assess: Is the tobacco user willing to make a quit attempt at this time?
      • Assist: If user is willing to attempt, refer for individual or group counseling and pharmacotherapy.
      • Arrange: Referrals to providers, agencies, and self-help groups. Monitor pharmacotherapy once quit date is established. U.S. Food and Drug Administration (FDA)-approved pharmacotherapies for smoking cessation are:
        • Bupropion SR (Zyban) and nicotine replacement products such as nicotine gum, nicotine inhalers, nicotine nasal spray, and nicotine patch. Psychoeducation about these medications is essential.
        • Zyban, for example, should not be combined with alcohol. Nurses working with in-patients in a case-management model were found to produce outcomes in smoking cessation (Smith et al., 2002; Daniel et al., 2004 [Level II]).
        • Communicate Caring and Concern:
          • Encourage moderate intensity exercise as a means of reducing cravings for nicotine because 5 minutes of such exercises is associated with short-term reduction in the desire to smoke and tobacco withdrawal symptoms (Daniel et al., 2004 [Level II]).
          • Arrange: Schedule follow-up contact in person or by telephone within 1 week after planned quit date. Continue telephone counseling for those using nicotine patches (Cooper et al, 2004; Boyle et al., 2005 [Level III]).
  • Smoking Marijuana: Little research regarding effective intervention for psychological dependence on marijuana is available. Some guidance can be found in smoking cessation and self-help approaches.
    • Refer to Steps for Smoking Cessation.
    • Refer patient to addiction specialist for counseling for psychological dependence and/or cognitive-behavioral therapy.
    • Refer to community-based self-help groups such as Narcotics Anonymous, Alcoholics Anonymous, and Al-Anon.
    • Encourage development or expansion of patient's social support system.
  • Heroin or Opioid Dependence
    • Older long-term opioid users may relapse and require treatment. Methadone or Buprenorphine are current pharmacological treatment options, effective in conjunction with self-help programs and/or psychosocial interventions. (National Institute for Drug Abuse, 2008 [Level IV]).
    • Treatment with methadone, a synthetic narcotic agonist, suppresses withdrawal symptoms and drug cravings associated with opioid dependence but requires daily dosing of 60 mg, minimum. It is dispensed only in specially licensed clinics.
    • Buprenorphine (Subutex or Suboxone), recently approved for use in office practice by trained physicians, is an opioid partial agonist-antagonist. Alone and in combination with Naloxone (Suboxone), it can prevent withdrawal when someone ceases use of an opioid drug and can be used for long-term treatment. Naloxone is an opioid antagonist used to reverse depressant symptoms in opiate overdose and at different dosages to treat dependence.
      • Close collaboration with the prescriber is required because these drugs should not be abruptly terminated, used with antidepressants, and interact negatively with many prescription medications.
    • Naltrexone, a long-acting opioid antagonist, blocks opioid effects and is most effective with those who are no longer opioid-dependent but are at high risk for relapse (Srisurapanont & Jarusuraisin, 2005 [Level III]).
    • Treatment of an older patient who has become addicted to oxycontin or other opioids should be done in consultation with an addictions specialist nurse or physician.
      • It is recommended that the prescriber avoid opioids and the synthetic opioids Demerol, Dilaudid, and Oxycontin. The opioids have high potential for addiction and Demerol has been associated with delirium in elders (Collins & Kleber, 2004 [Level VI]).
      • Barbiturates should be avoided for use as hypnotics and the use of benzodiazepines for anxiety should be limited to 4 months (USDHHS, 2004 [Level IV]).
  • Relapse Prevention
    • Monitor pharmacologic treatment such as Naltrexone as short-term treatment for alcohol dependence. The benefits of this treatment are dependent on adherence, and psychosocial treatment should accompany its use (World Health Organization [WHO], 2000 [Level I]). Methadone or Buprenorphine should be used for long-term treatment of opioid dependence.
    • Refer to community-based Alcoholics Anonymous, Narcotics Anonymous, Al-Anon groups, and encourage attendance.
    • Educate family and patient regarding signs of risky use or relapse to heavy drinking or alcohol-dependent behavior.
    • Counsel patient to reduce drug use (Harm Reduction) and engage in relationship healing/building, community or intellectually rewarding activities, spiritual growth, which increase valued nondrinking rewards.
    • Counsel in the development of coping skills:
      • Anticipate and avoid temptation.
      • Learn cognitive strategies to avoid negative moods.
      • Make lifestyle changes to reduce stress, improve the quality of life, and increase pleasure.
      • Learn cognitive and behavioral activities to cope with cravings and urges to use.
      • Encourage development or expansion of patient's social support system.

Follow-Up Monitoring of Condition

  • Evaluate for increase in substance use/misuse associated with growing numbers of aging adults.
  • Increase outreach to targeted vulnerable populations.
  • Document chronic care needs of elders diagnosed with substance-related disorders.
  • Monitor alcohol use among older adults with chronic pain (Brennan, Schutte, & Moos, 2005 [Level III]).
  • Communicate findings to all members of the involved caregiver team.

Definitions:

Levels of Evidence

Level I: Systematic reviews (integrative/meta-analyses/clinical practice guidelines based on systematic reviews)

Level II: Single experimental study (randomized controlled trials [RCTs])

Level III: Quasi-experimental studies

Level IV: Non-experimental studies

Level V: Care report/program evaluation/narrative literature reviews

Level VI: Opinions of respected authorities/Consensus panels

Reprinted with permission from Springer Publishing Company: Capezuti, E., Zwicker, D., Mezey, M. & Fulmer, T. (Eds). (2008) Evidence Based Geriatric Nursing Protocols for Best Practice, (3rd ed). New York: Springer Publishing Company.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for selected recommendations.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Naegle M. Substance misuse and alcohol use disorders. In: Capezuti E, Zwicker D, Mezey M, Fulmer T, editor(s). Evidence-based geriatric nursing protocols for best practice. 3rd ed. New York (NY): Springer Publishing Company; 2008. p. 649-76. [71 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2008

GUIDELINE DEVELOPER(S)

Hartford Institute for Geriatric Nursing - Academic Institution

SOURCE(S) OF FUNDING

Hartford Institute for Geriatric Nursing

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Madeline Naegle

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from the Hartford Institute for Geriatric Nursing Web site.

Copies of the book Geriatric Nursing Protocols for Best Practice, 3rd edition: Available from Springer Publishing Company, 536 Broadway, New York, NY 10012; Phone: (212) 431-4370; Fax: (212) 941-7842; Web: www.springerpub.com.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on June 11, 2008. The information was verified by the guideline developer on August 4, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo